1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Nonalcoholic Steatohepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025

Nonalcoholic Steatohepatitis Therapeutics Industry: Forecasts to 2025

  • April 2016
  • 65 pages
  • ID: 3999393
In this report:
Over a period of ten years up to ##% of patients with NASH develop cirrhosis of the liver, and ##% die from the disease.
The market overview section includes epidemiology of Nonalcoholic steatohepatitis (NASH) by region, to provide a thorough analysis of the overall addressable global market for the NASH therapeutics.

Summary

Table of Contents

Nonalcoholic fatty liver disease is a disorder categorized by excess fat in the liver of people who drink little to no alcohol. No direct cause has yet been identified, however obesity and insulin resistance are believed to have main roles. Most often, NAFLD goes relatively undetected, as a liver can remain fatty without obstructing its function. Though, NAFLD can progress into a far more severe condition known as nonalcoholic steatohepatitis, a disease characterized by inflammation and irreversible cell death. NASH is a disease that advances over time. Over a period of ten years up to 20.0 percent of patients with NASH develop cirrhosis of the liver, and 10.0 percent die from the disease. At present, NASH is one of the leading causes of liver transplants in the U.S.A, with a considerable proportion of the general population currently suffering from the disease. NAFLD and NASH are both closely related to diabetes and obesity, and together are now considered as the leading cause of liver disease in Western countries. Therefore, there is an urgent need for effective treatment options for these diseases. The need for treatment is forecast to propel the growth of NASH therapeutics in coming years.

The NASH market is divided based on drug type wich contains thinkable phase III candidates including Obeticholic acid, Aramchol, Saroglitazar and Elafibranor. Also, the industry report offers a list of the candidates in Phase I and Phase II clinical trials. Established on the drug type, Elafibranor is forecast to account for a main share of this market succeeded by Obeticholic Acid market and the sector for Elafibranor is forecast to grow at the more important Compound annual growth rate.

The section 'market overview' of this report demonstrates main market dynamics including drivers, market restraints, and alternatives that impact the current and future status of the industry. The market survey part includes epidemiology of Nonalcoholic steatohepatitis by region, to offer a thorough analysis of the global addressable overall market for the NASH therapeutics. Furthermore, the study offers qualitative information about diagnosis and treatment of NASH.

The analysis also offers crucial recommendations for market actors and new sector entrants. These recommendations would enable existing market players to expand their market shares and help additional companies to establish their presence in the NASH market across different areas worldwide. The market research closes with the company profiles section, which comprises main information about top actors in the segment including financial overview, strategic management, and recent evolutions.

Top actors in this sector are Astazeneca Plc, Intercept Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., GENFIT SA, Gilead Sciences, Incorporated, Zydus Cadila, Immuron Ltd., Conatus Pharmaceuticals, and Tobira Therapeutics, Incorporated.

The Nonalcoholic Steatohepatitis Therapeutics segment has been split as follows:

Overall Nonalcoholic Steatohepatitis Therapeutics Market, By Drug Type

Summary

Plausible Drug Candidates in Phase III

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Anal Fistula Global Clinical Trials Review, H2, 2018

Anal Fistula Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Anal Fistula Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Anal Fistula Global Clinical Trials Review, H2, 2018" provides an overview of Anal Fistula clinical trials ...

Ureter Cancer - Pipeline Review, H2 2018

Ureter Cancer - Pipeline Review, H2 2018

  • $ 2000
  • October 2018

Ureter Cancer - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer - Pipeline Review, H2 2018, provides an overview of the ...

Alcoholic Hepatitis - Pipeline Review, H2 2018

Alcoholic Hepatitis - Pipeline Review, H2 2018

  • $ 2000
  • September 2018

Alcoholic Hepatitis - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2018, provides an overview ...


ref:plp2016

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on